[5-FAM]-Galanin (2-30)-[Cys] (Human)

[5-FAM]-WTLNSAGYLLGPHAVGNHRSFSDKNGLTS-[C]-amide

  • Description

  • Application Data

Description

Galanin (2-30) is a full agonist for the galanin receptor GALR2. Galanin (2-30) has an N-terminal carboxyfluorescein (5-FAM) and a C-terminal cysteine residue for site-directed conjugation.

See full description

Application Data

Catalogue number crb1100332
Molecular Weight 3558.6
Sequence (one letter code)

[5-FAM]-WTLNSAGYLLGPHAVGNHRSFSDKNGLTS-[C]-amide

Sequence (three letter code)

[5-FAM]-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-His-Ala-Val-Gly-Asn-His-Arg-Ser-Phe-Ser-Asp-Lys-Asn-Gly-Leu-Thr-Ser-[Cys]-NH2

Purity >95%
References

Weinshenker and Holmes (2016). Regulation of neurological and neuropsychiatric phenotypes by locus coeruleus-derived galanin. Brain Res. 1641: 320. PMID: 26607256.

Laque et al., (2013). Leptin receptor neurons in the mouse hypothalamus are colocalized with the neuropeptide galanin and mediate anorexigenic leptin action. Am. J. Physiol-Endocrinol. Metab. 304(9): E999. PMID: 23482448.

Manufactured in: United Kingdom
Data Sheet Material Safety Data Sheet (MSDS)

Galanin is predominantly an inhibitory neuropeptide expressed in humans and other mammals’ brains, spinal cords, and gut. Galanin signalling occurs through three G protein-coupled receptors. The functional role of galanin remains largely unknown; however, galanin is predominantly involved in the modulation and inhibition of neuron action potentials. Galanin has been implicated in many biologically diverse functions, including nociception, waking and sleep regulation, cognition, feeding, mood regulation and blood pressure regulation. Galanin appears to have neuroprotective activity as its biosynthesis is increased 2-10 fold upon axotomy and during seizure activity in peripheral tissues and the brain.

The clinical relevance of galanin is related to several chronic neural disorders, including Alzheimer’s disease, epilepsy, depression and cancer; those who suffer from type 2 diabetes mellitus, depression and Alzheimer’s disease often express high levels of galanin. Conversely, intervention with galanin agonists (for example, M617, M1145 and M1153) manifests anti-insulin resistance and anti-Alzheimer’s disease characteristics and ameliorates or reinforces depression-like behaviour. Specifically, activation of GAL2 can alleviate such disease features in human and rodent models. This galanin (2-30) peptide has been used to characterise galanin’s binding sites and affinity for GALR receptors via competition binding analysis. Galanin (2-30) is a full agonist of the GALR2 receptor compared to its affinity for GALR1.

Galanin (2-30) is provided with an N-terminal 5-FAM, a widely used green fluorescent reagent ideal for peptide labelling and detection and a C-terminal cysteine for site-specific conjugation. The excitation/emission for this reagent is 490 nm/520 nm. Cambridge Research Biochemicals is a custom peptide provider. If you desire an alternate dye, please contact us to request a custom synthesis.

[5-FAM]-Galanin (2-30)-[Cys] (Human)

Cat No.Pack SizePriceQty.
1mg£170.00
0.5mg£110.00
Bulk Quote

You may also like…